Myeloid Neoplasm With Eosinophilia and FIP1L1-PDGFRA Rearrangement Treated With Imatinib Mesylate: A Pediatric Case With Long-term Follow-up

J Pediatr Hematol Oncol. 2019 May;41(4):334-335. doi: 10.1097/MPH.0000000000001446.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Antineoplastic Agents / therapeutic use*
  • Eosinophilia / etiology*
  • Humans
  • Imatinib Mesylate / therapeutic use*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Male
  • Oncogene Proteins, Fusion / genetics*
  • Receptor, Platelet-Derived Growth Factor alpha / genetics*
  • mRNA Cleavage and Polyadenylation Factors / genetics*

Substances

  • Antineoplastic Agents
  • Oncogene Proteins, Fusion
  • mRNA Cleavage and Polyadenylation Factors
  • Imatinib Mesylate
  • FIP1L1-PDGFRA fusion protein, human
  • Receptor, Platelet-Derived Growth Factor alpha